Clarithromycin modulates immune responses in experimental peritonitis

International Journal of Antimicrobial Agents

Volumn 37, Issue 4, 2011, Pages 347-351

  Atmatzidis, Stefanos ^a   Koutelidakis, Ioannis ^a   Chatzimavroudis, Grigorios ^a   Louis, Konstantinos ^b   Pistiki, Aikaterini ^b   Roditis, Konstantinos ^b   Atmatzidis, Konstantinos ^a   Giamarellos Bourboulis, Evangelos J ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apoptosis; Clarithromycin; Peritonitis; TNF

Indexed keywords

CLARITHROMYCIN; LIPOPOLYSACCHARIDE; PIPERACILLIN PLUS TAZOBACTAM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; BLOOD SAMPLING; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENTEROBACTER CLOACAE; ENTEROCOCCUS; ESCHERICHIA COLI; FLOW CYTOMETRY; IMMUNOMODULATION; LYMPHOCYTE; MALE; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONITIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RABBIT; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; LYMPHOCYTES; MALE; PERITONITIS; RABBITS;

EID: 79952816978     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.11.037     Document Type: Article

References (14)

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
2. Rittisch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nature Immunol 2008;8:776-86.
3. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2003;34:1084-93.
4. Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V, Mouktaroudi M, et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2004;48:93-9. (Pubitemid 38040182)
5. Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, Koutoukas P, Kousoulas V, Sabracos L, et al. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli. Int J Antimicrob Agents 2005;25:168-72. (Pubitemid 40138955)
6. Giamarellos-Bourboulis EJ, Adamis T, Sabracos L, Raftogiannis M, Baziaka T, Tsaganos T, et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 2005;37:48-54. (Pubitemid 40227740)
7. Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P, Tsaganos T, Tziortzioti V, et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2006;6:31.
8. Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Antonopoulou A, Adamis T, et al. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2006;57:937-44.
9. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, Plachouras D, Kollias S, Raftogiannis M, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008;46:1157-64. (Pubitemid 351589897)
10. Hodgin KE, Moss M. The epidemiology of sepsis. Curr Pharm Des 2008;14:1833-9.
11. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008;26:711-5. (Pubitemid 351905818)
12. Li C, Nikolau DP, Lister PD, Quintiliani R, Nightingale CH. Pharmacodynamic study of β-lactams alone and in combination with β-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible β-lactamase. J Antimicrob Chemother 2004;53:297-304.
13. Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa P, et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 2010;14:R96.
14. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004;54:21-8. (Pubitemid 39028963)